Methods of administering Anti-TNF(ALPHA) antibodies
MYPI2002002103A0Inactive Publication Date: 2002-12-08ABBVIE BIOTECHNOLOGY LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MYPI2002002103
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2001-06-08
- Filing Date
- 2002-06-06
- Publication Date
- 2002-12-08
- Estimated Expiration
- Not applicable · inactive patent
Abstract
METHODS OF TREATING DISORDERS IN WHICH TFNa ACTIVITYIS DETRIMENTALVIA BIWEEKLY, SUBCUTANEOUS ADMINISTRATION OF HUMAN ANTIBODIES, PREFERABLY RECOMBINANT HUMAN ANTIBODIES, THAT SPECIFICALLY BIND TO HUMAN TUMOR NECROSIS FACTOR a (hTNFa) ARE DISCLOSED. THE ANTIBODY MAY BE ADINISTERED WITH OR WITHOUTMETHOTREXATE. THESE ANTIBODIES HAVE HIGH AFFINITY FOR hTNFa(E.G.,KD=10-8 M OR LESS), A SLOW OFF RATE FOR hTNFa DISSOCIATION (E.G.,KOFF=10-3 SEC-1 OR LESS) AND NEUTRALIZE hTNFa ACTIVITY IN VITRO AND IN VIVO. AN ANTIBODY OF THE INVENTION CAN BE A FULL-LENGHT ANTIBODY OR AN ANTIGEN-BINDING PORTION THEREOF. KITS CONTAINING A PHARMACEUTICAL COMPOSITION AND INSTRUCTIONS FOR DOSING, AND PRELOADED SYRINGES CONTAINING PHARMACEUTICAL COMPOSITIONS ARE ALSO ENCOMPASSED BY THE INVENTION.
Need to check novelty before this filing date? Find Prior Art
